Last reviewed · How we verify
Placebo (for Bezafibrate)
Placebo produces no pharmacological effect and serves as a control comparator in clinical trials.
Placebo produces no pharmacological effect and serves as a control comparator in clinical trials. Used for Control arm in Phase 3 trial of Bezafibrate (fibrate for dyslipidemia/cardiovascular risk reduction).
At a glance
| Generic name | Placebo (for Bezafibrate) |
|---|---|
| Also known as | Does not apply |
| Sponsor | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Placebo is an inert substance administered in blinded clinical trials to establish baseline efficacy and safety profiles of the active comparator drug (in this case, Bezafibrate). It allows researchers to distinguish true drug effects from natural disease progression and psychological expectation effects. In this Phase 3 trial context, placebo serves as the control arm against which Bezafibrate's efficacy and tolerability are measured.
Approved indications
- Control arm in Phase 3 trial of Bezafibrate (fibrate for dyslipidemia/cardiovascular risk reduction)
Common side effects
Key clinical trials
- Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Participants With PBC (PHASE2)
- Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC (PHASE2)
- Phase 3 Study of Bezafibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis (PHASE3)
- A Study to Assess Efficacy and Safety of Bezafibrate in Patients With Primary Biliary Cholangitis (PHASE3)
- Efficacy and Safety of Alirocumab in Patients With Hypercholesterolemia Not Adequately Controlled With Non-statin Lipid Modifying Therapy or the Lowest Strength of Statin (PHASE3)
- Use of Bezafibrate in Patients With Primary Biliary Cirrhosis to Archive Complete Biochemical Response in Non-responders (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: